Surgical Resection and Pazopanib Treatment for Recurrent Cardiac Angiosarcoma

Cardiac sarcoma treatment is challenging for surgeons because of frequent tumor recurrence and poor prognosis. In addition, optimal management of recurrences is not well established. The multi-targeted tyrosine kinase inhibitor, pazopanib, was recently approved for soft-tissue sarcoma. Herein, we pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Yuki, Toda, Koichi, Miyagawa, Shigeru, Yoshikawa, Yasushi, Hata, Hiroki, Domae, Keitaro, Matsuura, Ryohei, Sawa, Yoshiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546942/
https://www.ncbi.nlm.nih.gov/pubmed/31211293
http://dx.doi.org/10.1177/2632010X19831261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546942/
https://www.ncbi.nlm.nih.gov/pubmed/31211293
http://dx.doi.org/10.1177/2632010X19831261

Ejemplares similares